ERBB2 and cancer: Currently, immune checkpoint inhibitors (ICIs) are an essential component in the treatment of G/GEJ cancer, regardless of the human epidermal growth factor receptor 2(HER2) status or the expression status of programmed cell death 1 ligand 1 (PD-L1).